Robert Iannone Biography and Net Worth

Robert Iannone has been Jazz’s executive vice president and global head of research and development since May 2019. Dr. Iannone oversees all aspects of preclinical research and clinical development, clinical operations and regulatory affairs. Dr. Iannone brings more than 18 years of experience in clinical drug development, having worked across therapeutic areas and phases of development, most recently on immuno-oncology programs at Merck, AstraZeneca and Immunomedics.

What is Robert Iannone's net worth?: The estimated net worth of Robert Iannone is at least $4.47 million as of December 9th, 2022. Dr. Iannone owns 36,316 shares of Jazz Pharmaceuticals stock worth more than $4,465,779 as of December 21st. This net worth approximation does not reflect any other assets that Dr. Iannone may own. Additionally, Dr. Iannone receives an annual salary of $1,190,000.00 as EVP at Jazz Pharmaceuticals. Learn More about Robert Iannone's net worth.
How old is Robert Iannone?: Dr. Iannone is currently 57 years old. There are 7 older executives and no younger executives at Jazz Pharmaceuticals. The oldest executive at Jazz Pharmaceuticals is Mr. Bruce C. Cozadd, Co-Founder, Chairman & CEO, who is 60 years old. Learn More on Robert Iannone's age.
What is Robert Iannone's salary?: As the EVP of Jazz Pharmaceuticals plc, Dr. Iannone earns $1,190,000.00 per year. There are 2 executives that earn more than Dr. Iannone. The highest earning executive at Jazz Pharmaceuticals is Mr. Bruce C. Cozadd, Co-Founder, Chairman & CEO, who commands a salary of $2,440,000.00 per year. Learn More on Robert Iannone's salary.
How do I contact Robert Iannone?: The corporate mailing address for Dr. Iannone and other Jazz Pharmaceuticals executives is FIFTH FLOOR WATERLOO EXCHANGE WATERLOO ROAD, DUBLIN L2, D04. Jazz Pharmaceuticals can also be reached via phone at (531) 634-7800 and via email at [email protected]. Learn More on Robert Iannone's contact information.
Has Robert Iannone been buying or selling shares of Jazz Pharmaceuticals?: Robert Iannone has not been actively trading shares of Jazz Pharmaceuticals during the last quarter. Most recently, Robert Iannone sold 1,844 shares of the business's stock in a transaction on Friday, December 9th. The shares were sold at an average price of $151.54, for a transaction totalling $279,439.76. Following the completion of the sale, the executive vice president now directly owns 36,316 shares of the company's stock, valued at $5,503,326.64. Learn More on Robert Iannone's trading history.
Who are Jazz Pharmaceuticals' active insiders?: Jazz Pharmaceuticals' insider roster includes Paul Berns (Director), Patricia Carr (SVP), Jennifer Cook (Director), Bruce Cozadd (Co-Founder, Chairman & CEO), Patrick Enright (Director), Renée Galá (CFO), Peter Gray (Director), Mary Henderson (SVP, Technical Operations), Robert Iannone (EVP), Philip Johnson (CFO), Finbar Larkin (SVP), Seamus Mulligan (Director), Kenneth O'Keefe (Director), Anne Oriordan (Director), Neena Patil (Insider), Samantha Pearce (SVP), Kim Sablich (EVP), Elmar Schnee (Director), Mark Smith (Director), Christopher Tovey (COO), and Rick Winningham (Director). Learn More on Jazz Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Jazz Pharmaceuticals?: During the last year, Jazz Pharmaceuticals insiders bought shares 1 times. They purchased a total of 12,000 shares worth more than $1,435,800.00. During the last year, insiders at the specialty pharmaceutical company sold shares 8 times. They sold a total of 15,262 shares worth more than $1,766,604.30. The most recent insider tranaction occured on December, 2nd when CEO Bruce C Cozadd sold 2,000 shares worth more than $242,340.00. Insiders at Jazz Pharmaceuticals own 4.2% of the company. Learn More about insider trades at Jazz Pharmaceuticals.
Information on this page was last updated on 12/2/2024.

Robert Iannone Insider Trading History at Jazz Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
12/9/2022	Sell	1,844	$151.54	$279,439.76	36,316

Robert Iannone Buying and Selling Activity at Jazz Pharmaceuticals

Jazz Pharmaceuticals Company Overview

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.

Today's Range

Now: $122.97

$121.37

$124.39

50 Day Range

MA: $118.89

$108.05

$127.74

2 Week Range

Now: $122.97

$99.06

$134.17

Volume

1,767,343 shs

Average Volume

675,822 shs

Market Capitalization

$7.43 billion

P/E Ratio

17.32

Dividend Yield

N/A

Beta

0.57

Did You See Trump’s Bombshell Exec. Order 001?

From Banyan Hill Publishing | Ad

Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minutes of stepping into the Oval Office...

I put all the details together for you here — but please hurry.

Robert Iannone Biography and Net Worth

What is Robert Iannone's net worth?

How old is Robert Iannone?

What is Robert Iannone's salary?

How do I contact Robert Iannone?

Has Robert Iannone been buying or selling shares of Jazz Pharmaceuticals?

Who are Jazz Pharmaceuticals' active insiders?

Are insiders buying or selling shares of Jazz Pharmaceuticals?